Provided by Tiger Fintech (Singapore) Pte. Ltd.

CureVac B.V.

2.72
+0.07002.64%
Post-market: 2.66-0.0600-2.21%18:47 EDT
Volume:589.68K
Turnover:1.62M
Market Cap:610.13M
PE:-2.04
High:2.89
Open:2.82
Low:2.66
Close:2.65
Loading ...

CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025

ACCESS Newswire
·
Yesterday

CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer

ACCESS Newswire
·
07 Apr

Is CureVac (CVAC) the Best German Stock to Buy According to Hedge Funds?

Insider Monkey
·
03 Apr

CureVac (CVAC) Gets a Hold from Leerink Partners

TIPRANKS
·
31 Mar

BUZZ-U.S. STOCKS ON THE MOVE-GameStop, Oxford Industries, Wolfspeed

Reuters
·
29 Mar

U.S.-Listed Shares of CureVac Rise 15.3% After Co's Mrna Patent Upheld by European Patent Office

THOMSON REUTERS
·
28 Mar

U.S.-Listed Shares of CureVac Rise 16% Premarket After Co's Mrna Patent Upheld by European Patent Office

THOMSON REUTERS
·
28 Mar

BUZZ-U.S. STOCKS ON THE MOVE -CureVac, gold miners, Rocket Lab

Reuters
·
28 Mar

CureVac Patent Validated in BioNTech Dispute, Infringement Hearing Set for July

MT Newswires Live
·
28 Mar

CureVac says European Patent Office dismissed BioNTech opposition

TIPRANKS
·
28 Mar

BUZZ-CureVac rises on COVID vaccine patent decision

Reuters
·
28 Mar

CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE

ACCESS Newswire
·
28 Mar

BRIEF-Curevac Receives Positive Validity Decision From European Patent Office In Litigation Against Biontech SE

Reuters
·
28 Mar

Eqs-News: CureVac Receives Positive Validity Decision From European Patent Office in Litigation Against BioNTech Se

THOMSON REUTERS
·
28 Mar

CureVac N.V.'s (NASDAQ:CVAC) largest shareholders are individual investors with 38% ownership, private equity firms own 31%

Simply Wall St.
·
10 Mar

CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World’s Top Innovators

ACCESS Newswire
·
18 Feb